- Accesswire•2 days agoResearch Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
- PR Newswire•3 days agoResverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
CALGARY, Feb. 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) today announced the receipt of the final minutes of an in-person Type B meeting with the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to request written comments, recommendations and feedback on Resverlogix's proposed protocol for its Phase 2a kidney dialysis trial. The primary objective of the study will be to evaluate if treatment with apabetalone in combination with standard of care (SoC) decreases alkaline phosphatase in comparison to placebo and SoC.
- CNW Group•13 days agoResverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
RVX.TO : Summary for RESVERLOGIX CORP. - Yahoo Finance
Resverlogix Corp. (RVX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||1.82 - 1.92|
|52 Week Range||1.10 - 2.47|
|PE Ratio (TTM)||-5.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|